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INTRODUCTION
As meningococcal serogroup C (MenC) disease occurs primarily in infants and teenagers, the introduction of MenC conjugate (MCC) vaccination into the U.K. immunisation schedule in 1999 was complemented by a catch-up vaccination campaign to 18 years of age (1) . This led to rapid and marked reductions in disease incidence (1), attributable deaths (2) , and carriage (3, 4) , with evidence of herd protection (5). However, poor antibody persistence was observed in infants and young children (6, 7), raising concerns about sustained protection since persistent serum bactericidal antibody (SBA) determines long-term efficacy (8). To extend antibody persistence, in 2006 the immunisation schedule was restructured to two priming MCC doses in infancy, using vaccines conjugated to either tetanus toxoid (TT) (NeisVac-C®) or a diphtheria toxin variant, CRM197 (CRM) (Menjugate® or Meningitec®); and a booster at 12 months of age using Menitorix® (MCC-TT plus Haemophilus influenza type b (Hib)). Despite this, antibody persistence remained poor (9).
To ensure protective antibody through the teenage years, which is a high-risk period for disease and carriage (4), a teenage MCC booster dose was introduced from 2013 (10) to directly protect vaccinees and help ensure maintenance of herd protection in the UK. However, it remains unclear how the different vaccines used in the childhood immunisation schedule would affect booster responses in teenagers.
Response to MCC booster given at 12 months of age depends on the primary vaccine given, with post-booster MenC SBA titers higher in children primed with MCC-TT than those primed with MCC-CRM (9). In children primed with MCC-TT, Hib-MCC-TT, or MCC-CRM, and then given MCC-TT at age 13-14 months, the Manuscript   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 MenC-protected proportion (SBA titers ≥8) at 5 years post booster was highest in those primed with MCC-TT (11). Better understanding of these interactions between priming and booster vaccines and carrier proteins would help further inform meningococcal vaccination policy, but this has not previously been studied in teenagers.
To investigate this, we identified a cohort of teenagers who were randomised to receive either MCC-TT (NeisVac-C®) or MCC-CRM (Meningitec® or Menjugate®) at age 3.5-6 years during a trial conducted before the national introduction of MCC in 1999 (12), and were thus ideally suited to assess the response to a CRM or TT- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
METHODS

Participants were recruited from a cohort of teenagers in Hertfordshire and
Gloucestershire, England, who were randomised to receive a single dose of MCC between 3.5 and 5.9 years of age, during a previous study between January 1998 and May 2000 (12) (Figure 1 ). Healthy volunteers from that cohort who were still locally available, eligible, and provided written consent, were grouped by primary vaccine and randomised to receive either CRM-conjugated or TT-conjugated MenACWY booster. Sera were collected before; 28 days after, and either 6 or 9 months after booster to allow modelling of antibody decline by time since booster.
Seroprotected proportions (SBA titers ≥8), ≥4-fold rises in SBA titer, SBA geometric mean titers (GMTs), and IgG geometric mean concentrations (GMCs) were calculated. Pre-boost antibody levels were compared by primary vaccine using a Kruskal-Wallis test, while normal errors regression modelling was used to analyse post-vaccination measurements (see further details in Supplemental Digital Content 1 (SDC-1)). Antibody data were modelled as log-titer against log-time to assess decline over time using a fixed effects model to allow for decline in individual responses, as previously described (9). The aim of the trial was to estimate the percentages of subjects achieving protective antibody levels in each treatment group with 95% CI widths ≤ ±10% (assumed observed percentage ≥90%), needing a sample size of 50 in each study group. However it was acknowledged from the outset that recruitment was unpredictable due to the strictly restricted pool of potential participants drawn from a specific previous study cohort. The eventual numbers recruited were lower than aimed, with corresponding effects on estimates precision and detectable differences. The subset of children who participated in the current study were similar to those who did not, with respect to age at preschool 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 vaccination and the proportions that received each of the three primary MCC vaccines, while gender proportions differed (38.7% male among current study participants, compared to 52.1% among non-participants, p=0.02). The primary response to MCC vaccine in the original study was similar between the current study participant subset and non-participants (Table S1 in SDC-2).
MenACWY conjugate vaccines were provided by the manufacturers. Novartis MenACWY contains capsular oligosaccharides conjugated to CRM197 (15), while GSK MenACWY is conjugated to TT (16-18). Primary vaccines used in the original study were previously described (12). Reactions were monitored via telephone, self-completed diary, and enquiry at study visits. 
RESULTS
A total of 93 teenagers were enrolled (Figure 1 ), aged 16-19 years, with a period of 12-14 years between primary (preschool) and booster (teenage) vaccination. Preboost, 1-month post-boost, and persistence blood samples were provided by 93, 92 and 91 participants, respectively.
Pre-boost serology:
Teenagers who were randomised for primary vaccination with MCC-TT had significantly higher MenC SBA GMT than those primed with either of the MCC-CRM primary vaccines (p=0.02). Also, a relatively greater proportion of them still had protective SBA titer, although confidence intervals overlapped with the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 MCC-CRM-primed groups (Table 1) . Individual-level data from the original preschool study was accessed to compare historical post-primary titers (after MCC vaccination ≥12 years previously) with corresponding pre-MenACWY booster titers obtained in the current study. Whilst most individual SBA titers had waned since priming, postprimary and pre-boost SBA titers ( Figure 2 ) were positively associated (rank correlation r = 0.45 with all data or 0.57 excluding two participants with post-primary titer <8). Notably, 73% (11/15) of the highest initial responders (SBA titer ≥8192) still had titers ≥8 over a decade later, compared with 25% (6/24) of those with more moderate post-primary titers (64-4096).
Participants had raised tetanus and diphtheria antibody levels, which was as anticipated since vaccines against both are included in UK routine immunisation schedules.
Post-boost MenC serology:
One month post-booster, 100% of participants achieved protective serogroup-specific SBA responses against all four meningococcal serogroups, except for 2% for MenY in those boosted with MenACWY-CRM (Table 2) . When categorised by primary vaccine (Table 1) there was also 100% seroprotection in all categories, except for 3% for MenY in those primed with MCC-TT. Therefore a limited number of MCC-TT-primed individuals who received CRM-conjugated booster did not achieve MenY seroprotection. Protected proportions were similar whether gauged by the ≥8 titer threshold or conservatively by ≥128 (not shown). SBA titers showed evidence of an interaction between the primary vaccine and the booster given (p=0.03). This appeared to arise from MenACWY-TT generating significantly (p<0.001) higher SBA titers in those primed with MCC-TT (GMT ~ 6400, 4800, 21600 for Menjugate, Meningitec and NeisVac-C, respectively); whereas MenACWY-CRM-boosted individuals showed no difference (p=0.81) by primary vaccine (GMT ~ 11100, 13000, 11100 for Menjugate, Meningitec and NeisVac-C, respectively) ( Figure 3 ; and see Table S2 Table S3 in SDC-5). Overall this meant that Novartis MenACWY-CRM vaccine gave significantly higher MenC titers than MenACWY-TT (p=0.02, adjusted for primary vaccination and time since vaccination) (1.97-fold difference, 95% CI 1.10 -3.53). Figure 3 b-d). Understandably, only MenACWY-TT increased tetanus IgG levels while MenACWY-CRM boosted diphtheria antibody (see SDC-6 (Table S4) , and SDC-7 (Table S5) 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Vaccine carrier protein influence: In our original pre-school study, MCC-TT was the most immunogenic primary vaccine (12), and MCC-TT-primed individuals in the current study had significantly higher SBA titers prior to boosting. For those primed with either of the two MCC-CRM vaccines, the composite (Menjugate® plus Meningitec®) proportion that still retained seroprotection before boosting was 32% (95%CI 21-46%), notably consistent with a UK serosurvey finding that 31.7% (23-42%) of those eligible for single-dose (mainly MCC-CRM) "catch-up" vaccination in England at toddler/preschool age had protective SBA titer after a decade (19). 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 This study also provided long-term (12-14 years) post-primary antibody persistence data in individuals primed at pre-school age. Approximately one-third to one-half of participants (depending on primary vaccine) were still putatively seroprotected, with significantly higher pre-boost MenC titers in those primed with MCC-TT. The age at primary vaccination may be crucial for the differential effect, as 5-year persistence after priming in older age cohorts (6-15 years) did not significantly differ between TT   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Conclusion: Both MenACWY vaccines stimulated protective functional antibody titers against all serogroups in 16-19 year olds primed over a decade earlier, regardless of the primary MCC vaccine received. Individuals primed and boosted with TT-conjugated vaccine had higher MenC SBA titers, but overall titers were higher with MenACWY-CRM. Childhood MCC vaccine priming followed by teenage MenACWY boosting could be a suitable option to broaden meningococcal protection without compromise to MenC population immunity in the UK . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Table Table 3 : Seroroup-specific IgG pre and post-booster vaccination, by booster vaccine Table Table 4 : Serogroup-specific IgG pre and post-booster vaccination, by primary vaccine and across all study groups contacted GPs to check their records. For 57 individuals, the records were inaccessible as GP configurations had either changed or their GPs were not able to participate in the checking process. Those who were confirmed to still be registered were invited to join this study, and eligible respondents were enrolled after providing fully informed written consent.
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Pre
Teenagers who received an MCC vaccine during the preschool study, but no further MCC vaccination thereafter, and no other vaccine within the 3 months preceding enrolment, were on logged teenage (current study) pre-boost titers, taking account of between-group differences in primary vaccine and booster vaccine. Comparisons across the 6 arms were by non-overlapping 95% CIs, being a conservative approach (equivalent to a P < 0.01 approximately) to allow for the high numbers of possible comparisons.
SUPPLEMENTAL DIGITAL CONTENT -RESULTS
The male/female distribution was 16 /30 (MenACWY-TT group) and 20/27 (MenACWY-CRM group). The median 1, 6 and 9-month post-booster intervals to blood sampling were 38 27 (range 17-42), 273 (251-306), and 189 (161-231) days, respectively. All were included in analysis as they were within pre-set time point limits. Per-protocol analysis only was carried out since there was no difference to modified intention-to-treat data. For all antigen group comparisons, age and gender were not associated with responses and not included in the models. 
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